Related Experiment Video
Updated: Jun 18, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE'
Giannis Mountzios1, Sofia Lampaki2, Helena Linardou3
1Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
Background:
The treatment landscape of non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly evolving with recent approvals of immunotherapies and targeted therapies.
Methods:
This retrospective study included 202 adults diagnosed with NM-NSCLC between 1 January 2018 and 31 December 2020 primarily aiming to capture initial management strategies.
Results:
Most frequent treatment patterns among Stage I/II patients (N = 84) were surgery only (48.8%) and surgery with adjuvant chemotherapy (with/without RT; 42.9%). Among Stage III patients (N = 118), most frequent patterns were chemotherapy plus radiotherapy (44.9%) and chemotherapy only (18.6%); 58.6% of Stage IIIA patients underwent surgery (of these, 32.4% also received chemotherapy and radiotherapy).
Conclusion:
Initial strategy was aligned with contemporary at that time European guidelines, setting a benchmark for understanding the future uptake of new therapies.
Insights
Treatment strategies for non-metastatic non-small cell lung cancer (NM-NSCLC) are evolving. This study captured initial management patterns for NM-NSCLC patients, providing a benchmark for future therapy adoption.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- The treatment landscape for non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly changing with new immunotherapies and targeted therapies.
- Understanding current treatment patterns is crucial for evaluating the adoption of novel therapeutic approaches.
Purpose of the Study:
- To capture and analyze the initial management strategies for non-metastatic non-small cell lung cancer (NM-NSCLC) patients.
- To establish a benchmark for understanding the uptake of new therapies in NM-NSCLC treatment.
Main Methods:
- Retrospective study of 202 adult patients diagnosed with NM-NSCLC.
- Data collected for patients diagnosed between January 1, 2018, and December 31, 2020.
- Analysis of initial treatment patterns based on cancer stage.
Main Results:
- For Stage I/II NM-NSCLC (N=84), the most common treatments were surgery alone (48.8%) and surgery with adjuvant chemotherapy (42.9%).
- For Stage III NM-NSCLC (N=118), primary treatments included chemoradiotherapy (44.9%) and chemotherapy alone (18.6%).
- A significant proportion of Stage IIIA patients (58.6%) received surgery, with 32.4% also undergoing chemotherapy and radiotherapy.
Conclusions:
- Initial treatment strategies for NM-NSCLC aligned with European guidelines contemporary to the study period.
- This study provides a baseline for assessing the impact of emerging immunotherapies and targeted therapies on NM-NSCLC management.
